Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease

BACKGROUND: Elevated intact parathyroid hormone (iPTH) levels can contribute to morbidity and mortality in children with chronic kidney disease (CKD). We evaluated the pharmacokinetics, efficacy, and safety of oral paricalcitol in reducing iPTH levels in children with stages 3–5 CKD. METHODS: Childr...

Descripción completa

Detalles Bibliográficos
Autores principales: Webb, Nicholas J. A., Lerner, Gary, Warady, Bradley A., Dell, Katherine M., Greenbaum, Larry A., Ariceta, Gema, Hoppe, Bernd, Linde, Peter, Lee, Ho-Jin, Eldred, Ann, Dufek, Matthew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440538/
https://www.ncbi.nlm.nih.gov/pubmed/28332096
http://dx.doi.org/10.1007/s00467-017-3579-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440538/
https://www.ncbi.nlm.nih.gov/pubmed/28332096
http://dx.doi.org/10.1007/s00467-017-3579-6

Ejemplares similares